Abiraterone Tablets: Targeted Therapy for Advanced Prostate Cancer and Hormone-Driven Cancers

Abiraterone is an androgen biosynthesis inhibitor used primarily in the treatment of prostate cancer, particularly in men with metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). By selectively inhibiting the CYP17 enzyme, Abiraterone reduces the body’s production of androgens (male hormones), which fuel the growth of prostate cancer cells.

Abiraterone:

• Blocks 17α-hydroxylase/C17,20-lyase (CYP17), an enzyme essential for androgen production in the testes, adrenal glands, and prostate tumor tissue

• Lowers circulating testosterone and other androgens

• Slows or halts the progression of androgen-sensitive cancers

  Primarily indicated for:

  • Prostate Cancer (mCRPC and mCSPC) in combination with prednisone

  Also under investigation or used off-label in select cases for:

  • Sickle Cell Anemia

  • Acute Lymphocytic Leukemia (ALL)

  • Soft Tissue Sarcoma

  • Hodgkin’s Disease

    Global Export Reach

    We export Abiraterone Tablets from India to healthcare markets across the globe, supplying high-quality and cost-effective oncology solutions to countries such as:

    • India, Venezuela, Brazil, Cambodia, Philippines, Nigeria, Myanmar, Thailand, Singapore, Russia, Kyrgyzstan, Tajikistan, Kenya, Zimbabwe, Somalia, Djibouti, Belarus, Macedonian, Turkey